Difficulty: Medium
Average Score: 81%
Practice
What is the first-line treatment for a neonate with meconium aspiration syndrome (MAS)?
Correct answer
B
Rationale
In the case of a neonate with meconium aspiration syndrome (MAS), the first-line treatment is positive pressure ventilation (Option B). This is because MAS can lead to airway obstruction and respiratory distress, requiring immediate intervention to support the baby's breathing. Positive pressure ventilation helps to open up the airways, improve oxygenation, and support adequate ventilation.
Option A, surfactant therapy, is not the first-line treatment for MAS. Surfactant therapy is typically used in neonatal respiratory distress syndrome (NRDS) to improve lung compliance by reducing surface tension in the alveoli. MAS, on the other hand, requires immediate respiratory support to address the airway obstruction caused by meconium.
Option C, antibiotic therapy, is not indicated for MAS as it is a condition related to meconium aspiration rather than a bacterial infection. Antibiotics would not address the primary issue of airway obstruction and respiratory distress in MAS.
Option D, inhaled nitric oxide, is not the first-line treatment for MAS. Inhaled nitric oxide is typically used in neonates with persistent pulmonary hypertension of the newborn (PPHN) to help vasodilate the pulmonary circulation and improve oxygenation. While MAS can lead to PPHN in some cases, the immediate focus in MAS management is on providing respiratory support.
In an educational context, understanding the appropriate treatment for MAS is crucial for pediatric nurses caring for neonates with respiratory distress. Recognizing the signs and symptoms of MAS and knowing the appropriate interventions can help nurses provide timely and effective care to improve outcomes for these vulnerable patients.
Option A, surfactant therapy, is not the first-line treatment for MAS. Surfactant therapy is typically used in neonatal respiratory distress syndrome (NRDS) to improve lung compliance by reducing surface tension in the alveoli. MAS, on the other hand, requires immediate respiratory support to address the airway obstruction caused by meconium.
Option C, antibiotic therapy, is not indicated for MAS as it is a condition related to meconium aspiration rather than a bacterial infection. Antibiotics would not address the primary issue of airway obstruction and respiratory distress in MAS.
Option D, inhaled nitric oxide, is not the first-line treatment for MAS. Inhaled nitric oxide is typically used in neonates with persistent pulmonary hypertension of the newborn (PPHN) to help vasodilate the pulmonary circulation and improve oxygenation. While MAS can lead to PPHN in some cases, the immediate focus in MAS management is on providing respiratory support.
In an educational context, understanding the appropriate treatment for MAS is crucial for pediatric nurses caring for neonates with respiratory distress. Recognizing the signs and symptoms of MAS and knowing the appropriate interventions can help nurses provide timely and effective care to improve outcomes for these vulnerable patients.